Genopis, is a newly established contract manufacturing organization (CMO) for developing & manufacturing gene therapy products. Genopis is established by a joint venture partnership between Medivate & a Korean biotech company, Viromed Co., Ltd. (public) which has multiple ongoing clinical programs, among which the PhIII trial for diabetic peripheral neuropathy (DPN) is the lead program. Genopis will begin manufacturing Viromedâs PhIII (DPN) products in 2019.
opathy (DPN) is the lead program. Genopis will begin manufacturing Viromedâs PhIII (DPN) products in 2019.